UA72248C2 - Dosage form containing phosphodiesterase inhibitor and method for treating sexual dysfunction - Google Patents
Dosage form containing phosphodiesterase inhibitor and method for treating sexual dysfunction Download PDFInfo
- Publication number
- UA72248C2 UA72248C2 UA2001118182A UA2001118182A UA72248C2 UA 72248 C2 UA72248 C2 UA 72248C2 UA 2001118182 A UA2001118182 A UA 2001118182A UA 2001118182 A UA2001118182 A UA 2001118182A UA 72248 C2 UA72248 C2 UA 72248C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compound
- dosage form
- buffer
- pde5
- inhibitor
- Prior art date
Links
- 201000001880 Sexual dysfunction Diseases 0.000 title abstract description 6
- 231100000872 sexual dysfunction Toxicity 0.000 title abstract description 6
- 239000002552 dosage form Substances 0.000 title description 20
- 238000000034 method Methods 0.000 title description 14
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract description 18
- 239000003112 inhibitor Substances 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 7
- 229940127557 pharmaceutical product Drugs 0.000 abstract description 7
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract description 2
- 239000002532 enzyme inhibitor Substances 0.000 abstract description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 50
- 230000000694 effects Effects 0.000 description 34
- 239000000203 mixture Substances 0.000 description 20
- 239000000872 buffer Substances 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 208000010228 Erectile Dysfunction Diseases 0.000 description 16
- 201000001881 impotence Diseases 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 11
- 101150098694 PDE5A gene Proteins 0.000 description 11
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000008187 granular material Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- 230000001568 sexual effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229960001681 croscarmellose sodium Drugs 0.000 description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 230000009986 erectile function Effects 0.000 description 6
- 239000000550 preparative sample Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
- 239000000006 Nitroglycerin Substances 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 229960003711 glyceryl trinitrate Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012907 medicinal substance Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 239000003998 snake venom Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010057671 Female sexual dysfunction Diseases 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 101100296723 Homo sapiens PDE5A gene Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000007580 dry-mixing Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 108010028584 nucleotidase Proteins 0.000 description 2
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 101150008289 Aox4 gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 208000021663 Female sexual arousal disease Diseases 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 108010091545 acetylleucyl-leucyl-norleucinal Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000005498 phthalate group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Formation And Processing Of Food Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Glass Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13203699P | 1999-04-30 | 1999-04-30 | |
| PCT/US2000/011129 WO2000066099A2 (en) | 1999-04-30 | 2000-04-26 | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA72248C2 true UA72248C2 (en) | 2005-02-15 |
Family
ID=22452153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001118182A UA72248C2 (en) | 1999-04-30 | 2000-04-26 | Dosage form containing phosphodiesterase inhibitor and method for treating sexual dysfunction |
Country Status (47)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2435816T3 (es) * | 1999-08-03 | 2013-12-23 | Icos Corporation | Formulación farmacéutica que comprende una Beta-carbolina y su uso para el tratamiento de la disfunción sexual |
| DE10010612A1 (de) * | 2000-03-03 | 2001-09-27 | Merck Patent Gmbh | Verwendung von PDE V-Inhibitoren |
| US20030153575A1 (en) * | 2000-06-08 | 2003-08-14 | Orme Mark W. | Tetracyclic diketopiperazine compounds as pdev inhibitors |
| JP4220775B2 (ja) * | 2000-08-02 | 2009-02-04 | リリー アイコス リミテッド ライアビリティ カンパニー | ホスホジエステラーゼ阻害剤としての融合複素環式誘導体 |
| JP4216709B2 (ja) * | 2001-06-05 | 2009-01-28 | リリー アイコス リミテッド ライアビリティ カンパニー | Ｐｄｅ５阻害剤としてのテトラ環状化合物 |
| GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| JP5823093B2 (ja) | 2006-03-28 | 2015-11-25 | ジャヴェリン ファーマシューティカルズ インコーポレイテッド | 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 |
| US7495024B2 (en) | 2006-08-07 | 2009-02-24 | Via Pharmaceuticals, Inc. | Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque |
| DE102007028869A1 (de) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
| DE102009033396A1 (de) | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung |
| US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
| US20110136815A1 (en) | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
| US20110263606A1 (en) * | 2010-04-26 | 2011-10-27 | Horst Zerbe | Solid oral dosage forms comprising tadalafil |
| WO2012107541A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
| EP2672959A1 (en) | 2011-02-10 | 2013-12-18 | Synthon BV | Granulated composition comprising tadalafil and a disintegrant |
| WO2012107092A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
| KR102239291B1 (ko) | 2013-06-28 | 2021-04-14 | 한미약품 주식회사 | 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제 |
| KR20150056443A (ko) | 2013-11-15 | 2015-05-26 | 한미약품 주식회사 | 타다라필 및 암로디핀을 포함하는 복합제제 |
| KR102646431B1 (ko) | 2017-09-29 | 2024-03-12 | 한미약품 주식회사 | 생산성 및 균일성이 개선된 타다라필을 함유하는 고형제제 및 그 제조방법 |
| US20210137919A1 (en) * | 2018-02-07 | 2021-05-13 | Smawa Gmbh | Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| GB9423911D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
| GB9511220D0 (en) * | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
| GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| GB9514473D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| YU49898A (sh) | 1996-05-10 | 2000-03-21 | Icos Corporation | Hemijska jedinjenja |
| SK285991B6 (sk) * | 1997-04-25 | 2008-01-07 | Pfizer Inc. | Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze |
| WO1999059584A1 (en) * | 1998-05-20 | 1999-11-25 | Schering Corporation | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
| AU1025899A (en) | 1998-09-16 | 2000-04-03 | Icos Corporation | Carboline derivatives as cgmp phosphodiesterase inhibitors |
| EP1120120A4 (en) * | 1998-10-05 | 2009-04-29 | Eisai R&D Man Co Ltd | TABLETS DISSOLVING DIRECTLY IN MOUTH |
| WO2000053148A2 (en) * | 1999-03-08 | 2000-09-14 | Merck & Co., Inc. | Methods and compositions for treating erectile dysfunction |
| EP1173167A4 (en) * | 1999-04-30 | 2004-07-14 | Lilly Icos Llc | TREATMENT OF FEMALE SEXUAL STIMULATION DISORDERS |
| US6451807B1 (en) * | 1999-04-30 | 2002-09-17 | Lilly Icos, Llc. | Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor |
-
2000
- 2000-04-25 IL IL13581700A patent/IL135817A0/xx unknown
- 2000-04-25 ES ES200001055A patent/ES2187234A1/es not_active Withdrawn
- 2000-04-25 SV SV2000000055A patent/SV2002000055A/es not_active Application Discontinuation
- 2000-04-25 NO NO20002097A patent/NO20002097L/no not_active Application Discontinuation
- 2000-04-25 HU HU0001632A patent/HUP0001632A3/hu unknown
- 2000-04-25 MX MXPA00003997A patent/MXPA00003997A/es unknown
- 2000-04-26 PE PE2000000388A patent/PE20010071A1/es not_active Application Discontinuation
- 2000-04-26 NZ NZ514882A patent/NZ514882A/en not_active IP Right Cessation
- 2000-04-26 GR GR20000100153A patent/GR1003575B/el unknown
- 2000-04-26 IT IT2000MI000922A patent/ITMI20000922A1/it unknown
- 2000-04-26 SG SG200002287A patent/SG98384A1/en unknown
- 2000-04-26 EP EP03023276A patent/EP1415652A3/en not_active Withdrawn
- 2000-04-26 SE SE0001518A patent/SE0001518L/xx not_active Application Discontinuation
- 2000-04-26 CN CNB008097771A patent/CN1196487C/zh not_active Expired - Lifetime
- 2000-04-26 DE DE20007861U patent/DE20007861U1/de not_active Expired - Lifetime
- 2000-04-26 IL IL14609800A patent/IL146098A0/xx unknown
- 2000-04-26 HU HU0200912A patent/HU230369B1/hu not_active IP Right Cessation
- 2000-04-26 ID IDP20000331D patent/ID25704A/id unknown
- 2000-04-26 BR BR0010181-8A patent/BR0010181A/pt not_active Application Discontinuation
- 2000-04-26 LV LVP-00-56A patent/LV12560B/en unknown
- 2000-04-26 BE BE2000/0295A patent/BE1012957A5/fr not_active IP Right Cessation
- 2000-04-26 SI SI200000107A patent/SI20361A/sl not_active IP Right Cessation
- 2000-04-26 ES ES00926367.4T patent/ES2208317T7/es active Active
- 2000-04-26 FR FR0005296A patent/FR2795646B1/fr not_active Expired - Fee Related
- 2000-04-26 DK DK200000677A patent/DK200000677A/da not_active Application Discontinuation
- 2000-04-26 CN CN00106987XA patent/CN1292264A/zh active Pending
- 2000-04-26 DE DE10021266A patent/DE10021266A1/de not_active Withdrawn
- 2000-04-26 KR KR1020017013747A patent/KR100577057B1/ko active IP Right Review Request
- 2000-04-26 DK DK00926367T patent/DK1173181T6/da active
- 2000-04-26 KR KR1020000022108A patent/KR20010020779A/ko not_active Application Discontinuation
- 2000-04-26 AT AT00926367T patent/ATE251908T1/de active
- 2000-04-26 SI SI200030225T patent/SI1173181T1/xx unknown
- 2000-04-26 MX MXPA01010837A patent/MXPA01010837A/es active IP Right Grant
- 2000-04-26 AU AU30129/00A patent/AU3012900A/en not_active Abandoned
- 2000-04-26 CO CO00029997A patent/CO5170493A1/es not_active Application Discontinuation
- 2000-04-26 IE IE20000315A patent/IE20000315A1/en not_active IP Right Cessation
- 2000-04-26 PL PL00339897A patent/PL339897A1/xx not_active Application Discontinuation
- 2000-04-26 DZ DZ003171A patent/DZ3171A1/xx active
- 2000-04-26 EP EP00926367.4A patent/EP1173181B3/en not_active Expired - Lifetime
- 2000-04-26 CH CH00819/00A patent/CH692478A5/de not_active IP Right Cessation
- 2000-04-26 HR HR20000243A patent/HRP20000243A2/hr not_active Application Discontinuation
- 2000-04-26 UA UA2001118182A patent/UA72248C2/uk unknown
- 2000-04-26 BR BR0003046-5A patent/BR0003046A/pt not_active IP Right Cessation
- 2000-04-26 LU LU90569A patent/LU90569B1/fr active
- 2000-04-26 WO PCT/US2000/011129 patent/WO2000066099A2/en active IP Right Grant
- 2000-04-26 FI FI20000976A patent/FI20000976A/fi not_active IP Right Cessation
- 2000-04-26 SK SK1563-2001A patent/SK285415B6/sk not_active IP Right Cessation
- 2000-04-26 PT PT102457A patent/PT102457A/pt unknown
- 2000-04-26 JP JP2000614984A patent/JP4975214B2/ja not_active Expired - Lifetime
- 2000-04-26 CZ CZ20013879A patent/CZ296534B6/cs not_active IP Right Cessation
- 2000-04-26 PT PT00926367T patent/PT1173181E/pt unknown
- 2000-04-26 CA CA002307101A patent/CA2307101C/en not_active Expired - Fee Related
- 2000-04-26 PL PL352629A patent/PL197813B1/pl unknown
- 2000-04-26 DE DE60005940.5T patent/DE60005940T3/de not_active Expired - Lifetime
- 2000-04-26 EA EA200000355A patent/EA200000355A3/ru unknown
- 2000-04-26 LT LT2000035A patent/LT4758B/lt not_active IP Right Cessation
- 2000-04-26 NL NL1015027A patent/NL1015027C2/nl not_active IP Right Cessation
- 2000-04-26 EA EA200101008A patent/EA005416B1/ru not_active IP Right Cessation
- 2000-04-26 NZ NZ504163A patent/NZ504163A/en unknown
- 2000-04-26 AU AU44908/00A patent/AU769946C/en not_active Expired
- 2000-04-26 ZA ZA200002058A patent/ZA200002058B/xx unknown
- 2000-04-26 JP JP2000126472A patent/JP2000336043A/ja active Pending
- 2000-04-26 CH CH00926367.4T patent/CH1173181H1/de unknown
- 2000-04-26 GB GB0010199A patent/GB2351663A/en not_active Withdrawn
- 2000-04-26 CA CA002371684A patent/CA2371684C/en not_active Expired - Lifetime
- 2000-04-26 TR TR2000/01132A patent/TR200001132A3/tr unknown
-
2001
- 2001-10-22 IL IL146098A patent/IL146098A/en not_active IP Right Cessation
- 2001-10-23 HR HR20010778A patent/HRP20010778B1/xx not_active IP Right Cessation
- 2001-10-29 ZA ZA200108900A patent/ZA200108900B/xx unknown
- 2001-10-29 NO NO20015275A patent/NO322013B3/no not_active IP Right Cessation
-
2002
- 2002-02-26 HK HK02101474.1A patent/HK1041204B/zh not_active IP Right Cessation
-
2004
- 2004-05-12 AU AU2004201988A patent/AU2004201988A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA72248C2 (en) | Dosage form containing phosphodiesterase inhibitor and method for treating sexual dysfunction | |
| US6943166B1 (en) | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction | |
| KR20030007551A (ko) | Ｐｄｅ5 억제제를 사용하여 발기 부전을 매일 치료하는 방법 | |
| Kovachevich et al. | Pharmacokinetics of acetaminophen administered in tablets and capsules under long-term space flight conditions | |
| US20030144296A1 (en) | Daily treatment for erectile dysfunction using a PDE5 inhibitor | |
| JP4285997B2 (ja) | 性的機能不全を予防および治療するための医薬の製造におけるｎ−アセチル−ｄ−グルコサミンの使用 | |
| Smith et al. | Treatment of allergic conjunctivitis with ocular decongestants | |
| KR20040032821A (ko) | 아데노신 트리포스페이트의 투여를 통한 근육 피로의 감소방법 | |
| RU2101014C1 (ru) | Анальгезирующее, противовоспалительное, жаропонижающее лекарственное средство и способ его получения |